Showing results (671-680 of 1,191) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|February 25, 2025
A Federated Data Analysis Approach for the Evaluation of Surrogate EndpointsDries De Witte, Ariel Alonso Abad, Diane Stephenson, et al.Pharmaceutical Statistics|August 6, 2024
Mixture Experimentation in Pharmaceutical Formulations: A TutorialLynne B Hare, Stan Altan, Hans CoppenollePharmaceutical Statistics|August 9, 2024
Bayesian Methods for Quality Tolerance Limit (QTL) MonitoringJ C Poythress, Jin Hyung Lee, Kentaro Takeda, et al.Pharmaceutical Statistics|June 26, 2024
Investigating Stability in Subgroup Identification for Stratified MedicineG M Hair, T Jemielita, S Mt-Isa, et al.Pharmaceutical Statistics|March 23, 2007
Weibull prediction of event times in clinical trialsGui-shuang Ying, Daniel F HeitjanPharmaceutical Statistics|November 4, 2006
Power and sample size considerations in clinical trials with competing risk endpointsEllen MakiPharmaceutical Statistics|November 4, 2006
Adapting the sample size planning of a phase III trial based on phase II dataSue-Jane Wang, H M James Hung, Robert T O'NeillPharmaceutical Statistics|November 4, 2006
Methodological issues with adaptation of clinical trial designH M James Hung, Sue-Jane Wang, Robert T O'NeillPharmaceutical Statistics|November 4, 2006
Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study designSatoshi Morita, Junichi SakamotoPharmaceutical Statistics|November 4, 2006
Review of guidelines and literature for handling missing data in longitudinal clinical trials with a case studyM Liu, L Wei, J ZhangPageof 120